Impact BioMedical Inc. (IBO) income statement
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $329.93MP/E –Yield –
Impact BioMedical Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- -1120.0%
- Operating margin
- -14597.1%
- Net margin
- 2254.3%
- Return on equity, FY2025
- -142.9%
Financial strength
- Current ratio
- 0.16
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 0.5%
Valuation
- P/E ratio
- –
- Price to sales
- 9426.66
- Price to book
- 30.65
- Dividend yield
- –
See a number that looks wrong?